Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial

INTRODUCTION: Once-weekly subcutaneous semaglutide, a glucagon-like peptide-1 analog, is approved in the USA as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes (T2D) to improve glycemic control and reduce the risk of major adverse cardiovascular events in peop...

Descripción completa

Detalles Bibliográficos
Autores principales: Buse, John B, Nordahl Christensen, Helene, Harty, Brian J, Mitchell, Julie, Soule, Benjamin P, Zacherle, Emily, Cziraky, Mark, Willey, Vincent J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163526/
https://www.ncbi.nlm.nih.gov/pubmed/37137527
http://dx.doi.org/10.1136/bmjdrc-2022-003206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163526/
https://www.ncbi.nlm.nih.gov/pubmed/37137527
http://dx.doi.org/10.1136/bmjdrc-2022-003206

Ejemplares similares